Entrinsic Bioscience Demonstrates Breakthrough GI Barrier Benefits
Entrinsic Bioscience, a pioneering life sciences company incubating at UF Innovate | Accelerate at Sid Martin Biotech, announced results from a new clinical study at renowned Monash University, in Melbourne, Australia. Entrinsic has successfully demonstrated the efficacy of two UF patent-protected formulas, utilizing precise combinations of amino acids, which enabled them to provide targeted gastrointestinal (GI) health and wellness benefits.
Applied Genetic Technologies exceeds enrollment target for SKYLINE trial of AGTC-501
Applied Genetic Technologies Corp. announced it had exceeded the enrollment target in the Company’s SKYLINE trial of AGTC-501, a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa (XLRP).
Tech Tuesday: Amend Surgical CEO Shows Off a Product Called Tissue Tape
A North Central Florida biotech company is working on a new product they say could help wounds heal better. For our revamped Tech Tuesday, our friends at UF Innovate tell us the company drew inspiration from a certain slimy animal.
RTI Surgical Announces Spin Off of Businesses into Two Independent Companies
UF startup RTI Surgical, a global private label OEM company, announced that the company will spin off its Metals business, creating two independent companies that are focused on the needs of customers and patients in their distinct market segments.
New and Upcoming Developments in Glaucoma Treatment
Glaucoma specialist, Dr. Amy Mehta, discusses new and upcoming developments in glaucoma treatment, including an advance by UF startup and UF Innovate | Accelerate at Sid Martin Biotech company TearClear.
Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant
Oragenics, Inc. announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant.
Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., in collaboration with researchers from Florida International University’s Department of Physics and Biomolecular Sciences Institute, announced the publication of a study entitled “Lipid II Binding and Transmembrane Properties of Various Antimicrobial Lanthipeptides.”
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
UF startup and Sid Martin Biotech alumni company Oragenics, Inc. announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.
Lacerta Therapeutics Appoints Min Wang, PhD, JD and Marc Wolff to Its Board of Directors
UF startup and UF Innovate | Accelerate at Sid Martin Biotech graduate Lacerta Therapeutics, Inc., a gene therapy company dedicated to the discovery and development of AAV-based gene therapies, appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors.
Talking About Feeling: Axogen Raises Awareness for Mastectomy Side Effect
In the wake of Breast Cancer Awareness Month, UF startup and UF Innovate | Accelerate at Sid Martin Biotech graduate Axogen has expanded the scope of a campaign to raise awareness about a side effect of mastectomies.
